Wondfo Heritage
From 1992 On
1992
1992
Wondfo was founded and became one of the earliest high-tech biological companies focusing on Point-of-Care testing in China.
1996
1996
The South China University of Technology invested in Wondfo and became one of the shareholders of Wondfo.
2001
2001
Wondfo was granted GMP certificate by China Food and Drug Administration.
2003
2003
Wondfo got CE certificate, FDA certificate, ISO 9001:2001 quality system certification and began entering the global market.
2006
2006
Wondfo got EN ISO13485 certificate.
2009
2009
Wondfo obtained ISO9001:2008 certification. Wondfo’s test kit for the Influenza A(H1N1) took the first place in the national quality appraisal.
2012
2012
Guangzhou Accurate and Correct Test Co., Ltd was set up, providing forensic toxicological analysis services.Wondfo was licensed as the "Key High-Tech Enterprise in National Torch Plan Project", and made preparations for a third-party detection institution.
2013
2013
Wondfo was approved to undertake the national research project “The control and prevention of serious infectious diseases, such as AIDS and virus hepatitis”, focusing on the research of the rapid diagnostic reagents for serious infectious diseases.
2014
2014
Wondfo was granted to undertake the national demonstration project in National Torch Plan Project, engaging in the research of the immunofluorescence quantitative detection equipment and reagents for miocardial infarction and heart failure.
2015
2015
Wondfo was listed on Shenzhen Stock Exchange, becoming the first public company in China's POCT field.
2018
2018
Wondfo has totally developed 9 technology platforms, including chemiluminescence, molecular diagnostics, and has set up 20+ subsidiaries worldwide to expand the global coverage.
 
2020
2020
Wondfo has been devoting all efforts to fighting against the COVID-19 pandemic since the outbreak and has developed reliable and high-performance 2019-nCoV RT-PCR, 2019-nCoV antigen, and 2019-nCoV antibody test kits successively, ideal for various applications, including screening in high-risk congregate, Sero-epidemiological investigation, etc. Wondfo is one of the companies that initially got the 2019-nCoV antibody test approved to the market in China.
Mission
Mission
We are specialized in providing professional healthcare products and services, and we sincerely safeguard people’s life and well being.
Vision
Vision
We’re dedicated to providing professional products and services of rapid diagnosis and chronic disease management;
We are always in the pursuit of a friendly and convenient user experience;
We strive to enhance people’s wellbeing and fulfill the shared dream of our staff, customers, and partners;
Core values
Core values
We strive to achieve goals with full passion to meet every customer’s needs;
We respect every employee and give them opportunities to constantly improve themselves;
We dare to dream and act to bring success to every partner;